knowledge -WSS

knowledge

author：knowledge 2025-09-30 21:39:57 - browse：51834

Outgoing Bristol CEO Giovanni Caforio Emilie Pickering for STAT

It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO Giovanni Caforio will step down. He’ll be replaced by Christopher Boerner, who is currently chief operating officer.

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market. But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion.

STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure. He also reflected on what it meant to be a physician — and the son of a physician. “We were speaking about patient stories over lunch and dinner, when I was a kid, and I think that drove my passion for medicine,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： FDA panel signals lack of confidence in Amgen cancer drug data

leisure time

hotspot

WSS

FDA rejects Alnylam's heart disease treatment over insufficient data

When women are denied an abortion, their children fare worse than peers

Colorectal cancer study finds potential in overlooked immune cell

Sana to lay off nearly a third of staff, de

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Food makers to regulators: Ultra

focus

knowledge

focus

Tori Bowie and the unacceptable rates of Black maternal death

Food makers to regulators: Ultra

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FDA panel signals lack of confidence in Amgen cancer drug data

What does generative AI mean for health care? We asked experts

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

As demand for Covid shots wanes, Moderna seeks its next success

PEPFAR is under serious threat — and so is global health

Duchenne breakthrough therapy leaves behind pioneering families

FDA rejects Alnylam's heart disease treatment over insufficient data

focus

Popular nasal decongestant doesn't actually relieve congestion

New weight loss drugs vying to be the next Wegovy or Mounjaro

AI can decode, harness the power of the humane immune system

Pig kidney works a record two months in donated body

How to make the FDA’s new prescription one

A virus, fished out of a lake, may have saved a man’s life

leisure time

hotspot

hotspot

focus